Biomedical research in the United States

Global Orphan Drug Market Projected to witness a Growth of 150% by 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 24, 2020
Health, Pharmaceutical, Health, Articles, Pharmaceuticals policy, Pharmaceutical industry, Drug discovery, Food and Drug Administration, Biotechnology law, Orphan drug, Clinical trial, Medication, Orphan Drug Act, Biomedical research in the United States

The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights:
    Global Orphan Drug Market Opportunity: US$ 300 Billion
    US Dominates Global Orphan Drug Market: 50% Market Share
    US Orphan Drug Opportunity To Surpass: US$ 150 Billion
    Global Orphan Drug Clinical Insight: More Than 900 Drugs
    Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
    Oncology To Dominate Orphan Drug Development: 35% Share
    The research report Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026 discusses about the recent trends and opportunities that the orphan drug market has brought into the pharmaceutical sector.
  • Orphan drugs market has been recently recognized as a promising therapeutic market as the diseases that are covered under the market are life-threatening diseases.
  • Earlier the orphan drug segment was overlooked by the big pharmaceutical companies as developing and marketing of these drugs was considered not so profitable.

$300 Billion Orphan Drugs Market Opportunity Assessment, 2026 - Insights Into Clinical Trials (900+ Drugs), Patents and Guidelines

Retrieved on: 
Wednesday, March 18, 2020
Health, Articles, Life sciences, Pharmaceuticals policy, Pharmaceutical industry, Drug discovery, Food and Drug Administration, Biotechnology law, Orphan drug, Medication, Clinical trial, Biomedical research in the United States

DUBLIN, March 18, 2020 /PRNewswire/ -- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 18, 2020 /PRNewswire/ -- The "Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Orphan Drug Market Opportunity: US$ 300 Billion
    US Dominates Global Orphan Drug Market: 50% Market Share
    US Orphan Drug Opportunity To Surpass: US$ 150 Billion
    Global Orphan Drug Clinical Insight: More Than 900 Drugs
    Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs
    Oncology To Dominate Orphan Drug Development: 35% Share
    This report discusses about the recent trends and opportunities that the orphan drug market has brought into the pharmaceutical sector.
  • Global Orphan Drug Market is Estimated to Witness 150% Market Growth by 2026, Compared to 2018
    Orphan drugs market has been recently recognized as a promising therapeutic market as the diseases that are covered under the market are life-threatening diseases.
  • Currently, more than 400 orphan designated drugs are commercially available in the marketed and close to 1000 drugs are undergoing clinical trials.

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)

Retrieved on: 
Friday, January 31, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Articles, Biotechnology, Biosimilar, Drugs, Pfizer, Biomedical research in the United States, Biopharmaceutical

"Biosimilars like RUXIENCE can play an important role in cancer care, helping to expand patient access to potentially life-changing therapies, said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.

Key Points: 
  • "Biosimilars like RUXIENCE can play an important role in cancer care, helping to expand patient access to potentially life-changing therapies, said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
  • If approved, RUXIENCE would become Pfizers fifth oncology biosimilar to receive regulatory approval in Europe.
  • The regulatory submission is supported by a comprehensive data package which demonstrates biosimilarity of RUXIENCE to the reference product.
  • At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients.

Alberta’s biosimilars policy: another significant step towards improving patient access to safe, effective, and high-quality medicines in Canada

Retrieved on: 
Thursday, December 12, 2019
Life sciences, Articles, Biotechnology, Biosimilar, Drugs, Health, RTT, Specialty drugs, Pharmaceutical industry, Biomedical research in the United States, Association for Accessible Medicines

After this period, Health Canada authorizes the sale of biosimilars, which have no expected clinically meaningful differences in efficacy and safety compared to their reference medicines.

Key Points: 
  • After this period, Health Canada authorizes the sale of biosimilars, which have no expected clinically meaningful differences in efficacy and safety compared to their reference medicines.
  • Biosimilar switch policies are an important step towards increasing patient access to high-quality, life-enhancing biosimilar medicines and realizing significant health system cost savings for the province, said Michel Robidoux, President and General Manager, Sandoz Canada.
  • We are encouraged to see another province take a step to improve adoption of biosimilars in Canada.
  • A leader in its field, Sandoz Canada markets and distributes a broad line of generic, biosimilar and specialty products.

Global Orphan Drugs Market Growth, Trends, and Forecast 2019-2024 - The Market is Expected to Register a CAGR of 11.5% - ResearchAndMarkets.com

Retrieved on: 
Friday, May 17, 2019
Health, Pharmaceutical, Articles, Pharmaceuticals policy, Health, Drug discovery, Orphan drug, Life sciences, Rare disease, Biomedical research in the United States

The "Orphan Drugs Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orphan Drugs Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years.
  • Currently, the average approval time for non-orphan drugs is around 13 months and the same for orphan drugs is much less at around 10 months.
  • North America currently dominates the market for orphan drugs and is expected to continue its stronghold for a few more years.

EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014

Retrieved on: 
Tuesday, April 30, 2019
Life sciences, Articles, Health, Biotechnology, Novartis, RTT, Specialty drugs, Biosimilar, Trastuzumab, Generic drug, Biomedical research in the United States, Intas Biopharmaceuticals

Sandoz is a Novartis division, and a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics.

Key Points: 
  • Sandoz is a Novartis division, and a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics.
  • Sandoz has a long history and extensive experience in the development and commercialization of biosimilar and cancer drugs in markets such as Europe and the United States.
  • The collaboration between EirGenix and Sandoz will leverage the combined strength of EirGenix 's R&D of biosimilar drugs, with Sandoz's substantial experience in global drug sales and advantages in market access.
  • EG12014 (Trastuzumab biosimilar) has entered a global Phase 3 clinical trial (Study No.

EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014

Retrieved on: 
Tuesday, April 30, 2019
Life sciences, Articles, Health, Biotechnology, Novartis, RTT, Specialty drugs, Biosimilar, Trastuzumab, Generic drug, Biomedical research in the United States, Intas Biopharmaceuticals

Sandoz is a Novartis division, and a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics.

Key Points: 
  • Sandoz is a Novartis division, and a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics.
  • Sandoz has a long history and extensive experience in the development and commercialization of biosimilar and cancer drugs in markets such as Europe and the United States.
  • The collaboration between EirGenix and Sandoz will leverage the combined strength of EirGenix 's R&D of biosimilar drugs, with Sandoz's substantial experience in global drug sales and advantages in market access.
  • EG12014 (Trastuzumab biosimilar) has entered a global Phase 3 clinical trial (Study No.

Orphan Drugs - Worldwide Market Outlook to 2023 by Disease Type, Product Type and Geography

Retrieved on: 
Friday, September 14, 2018
Pharmaceuticals policy, Health, Drug discovery, Orphan drug, Biotechnology, Rare disease, Pharmaceutical industry, Biomedical research in the United States

The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017.

Key Points: 
  • The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017.
  • During the forecast period, prescription sales in the orphan drug sector are projected to grow at twice the rate of the overall prescription market.
  • The orphan drug market is classified into various segments by disease types, indication, and geographical regions.
  • The global orphan drug market is expanding globally to cure rare diseases and thus expected to grow in all regions.

Global Orphan Drug Pipeline & Regulatory Insight Report 2018: A US$ 260 Billion Opportunity to 2025

Retrieved on: 
Tuesday, September 11, 2018
Health, Food and Drug Administration, Pharmaceuticals policy, Drug discovery, Orphan drug, Biotechnology, Drug pipeline, Biomedical research in the United States

The "Global Orphan Drug Pipeline & Regulatory Insight 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Orphan Drug Pipeline & Regulatory Insight 2025" report has been added to ResearchAndMarkets.com's offering.
  • Global Orphan Drug Pipeline & Regulatory Insight 2025 Report Highlights:
    Global Orphan Drug Market Overview: US$ 260 Billion Opportunity
    Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia
    Global Orphan Drug Clinical Pipeline Insight: 973 Drugs
    Marketed Orphan Drug Clinical Insight: 366 Drugs
    Global Orphan Drug Pipeline & Regulatory Insight 2025 report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of orphan drug market.
  • As per report findings, there are more than 350 orphan designated drugs commercially available in the market and more than 900 in the clinical pipeline.
  • Most of the orphan drugs in clinical pipeline are in Phase - II trials followed by Phase - III trials.

High-cost specialty drugs continue to dominate the new drug landscape

Retrieved on: 
Tuesday, June 26, 2018
Health, Pharmaceuticals policy, Biotechnology, Drug discovery, Orphan drug, Specialty drugs in the United States, Biomedical research in the United States

Important new drugs have been launched since 2009, accounting for nearly one quarter of brand-name drug sales in Canada by 2016.

Key Points: 
  • Important new drugs have been launched since 2009, accounting for nearly one quarter of brand-name drug sales in Canada by 2016.
  • In line with trends observed from 2009 to 2014, the study found that high-priced speciality drugs such as those used to treat rare diseases, biologic drugs and oncology drugs, continue to dominate the new drug landscape in 2015 and 2016, both in Canada and internationally.
  • Orphan drugs are increasingly dominating the new drug landscape, representing 54% of new drugs entering the market in 2015 and 42% in 2016, a significant increase from the 33% average from 2009 to 2014.
  • The number of oncology drugs continues to be high, representing 26% of the total new drugs in 2015 and 2016.